Zobrazeno 11 - 20
of 309
pro vyhledávání: ''
Publikováno v:
Oncogene. 39:5867-5875
Although the prognosis of advanced extramammary Paget's disease (EMPD) is poor, there have been no preclinical research models for the development of novel therapeutics. This study aims to establish a preclinical research model for EMPD. We transplan
Autor:
Frank Seeliger, Carla P. Martins, Emily James, Sandra Wimberger, Camilla Johansson, Mohammad Bohlooly-Y, Emma J. Davies, Maryam Clausen, Lukas Badertscher, Michelle J. Porritt, Simon T. Barry, Xiufeng Xu, Anna Schantz, Roberto Nitsch, Amir Taheri-Ghahfarokhi, Marcello Maresca, Himjyot Jaiswal, Elizabeth Hardaker, Jenna Bradley, Babak Alaeimahabadi, Lorenz M. Mayr, Abdel Wahad Bidar, Therese Admyre, Anders Lundin
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Nature Communications
Nature Communications
The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times
Autor:
Lan Wang, Wenhao Bao, Ning Hou, Han Chen, Jianan Yang, Danping Huang, Xuhong Chen, Xiangqin Kuang, Liangliang Ren, Chun Lin, Lili Jiang, Zhuojun Zhang, Zhongqiu Zhou, Hongbiao Huang, Libing Song, Jinyuan Pan
Publikováno v:
Cell Death and Disease, Vol 11, Iss 7, Pp 1-12 (2020)
Cell Death & Disease
Cell Death & Disease
HER2+ breast cancer (BC) is characterized by rapid growth, early recurrence, early metastasis, and chemoresistance. Trastuzumab is the most effective treatment for HER2+ BC and effectively reduces the risk of recurrence and death of patients. Resista
Autor:
Hyonchol Jang, Jae-Woong Min, Yura Song, Hee Yeon Kim, Eunyoung Lee, Shiv Poojan, Woong-Yang Park, Hye Won Sim, Seung-Hyun Bae, Eun-Kyung Kang, Kyeong-Man Hong, Young-Ho Kim, Yourae Hong, Hae-Ock Lee
Publikováno v:
Experimental and Molecular Medicine, Vol 52, Iss 7, Pp 1102-1115 (2020)
Experimental & Molecular Medicine
Experimental & Molecular Medicine
To elucidate the epigenetic mechanisms of drug resistance, epigenetically reprogrammed H460 cancer cells (R-H460) were established by the transient introduction of reprogramming factors. Then, the R-H460 cells were induced to differentiate by the wit
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-17 (2020)
Scientific Reports
Scientific Reports
Cisplatin is the first-line chemotherapeutic agent for the treatment of oral squamous cell carcinoma (OSCC). However, the intrinsic or acquired resistance against cisplatin remains a major obstacle to treatment efficacy in OSCC. Recently, mitochondri
Autor:
Hui-Chuan Sun, Zhao-You Tang, Bin Xu, Yunfei Xu, Yuan-Yuan Zhang, Xiao-Dong Zhu, Kang-Shuai Li, Wen-Kai Shi, Ming Lei, Shi-Zhe Zhang, Man-Qing Cao, Xiao-Long Li, Hongda Liu, Xue-Feng Liu, Nan Xiao
Publikováno v:
Cell Death and Disease, Vol 11, Iss 5, Pp 1-15 (2020)
Cell Death & Disease
Cell Death & Disease
Most hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage; however, the effect of systemic therapy on advanced HCC remains undetermined. Therefore, new treatment targets must be identified. We analyzed Gene Expression Omnibus da
Publikováno v:
Experimental and Molecular Medicine, Vol 52, Iss 4, Pp 643-657 (2020)
Experimental & Molecular Medicine
Experimental & Molecular Medicine
Chromosomal instability (CIN) in cancer cells has been reported to activate the cGAS–STING innate immunity pathway via micronuclei formation, thus affecting tumor immunity and tumor progression. However, adverse effects of the cGAS/STING pathway as
Autor:
Michael A. Rogers, Behnoush Kermanshahi, Saeed M. Ghazani, Katrina Tait, Matthew Tcheng, Richard W. Smith, Shannon P. Callender, Paul A. Spagnuolo, Shawn D. Wettig, William Tam, Nawaz Ahmed, Alessia Roma, Alejandro G. Marangoni
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
Avocado (Persea americana Mill.; Lauraceae) seed-derived polyhydroxylated fatty alcohols (PFAs) or polyols (i.e., avocadene and avocadyne) are metabolic modulators that selectively induce apoptosis of leukemia stem cells and reverse pathologies assoc
Autor:
Shinichiro Maeda, Takuya Shintani, Sachiyo Hanamuro, Ying Lin, Yuya Haga, Kazuma Higashisaka, Yasushi Fujio, Yasuo Tsutsumi, Hirofumi Tsujino, Ayaka Maki, Kazuya Nagano
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports
Scientific Reports
In non-small-cell lung cancer, mutation of epidermal growth factor receptor (EGFR) stimulates cell proliferation and survival. EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib are used as first-line therapy with drastic and immediate eff
Autor:
Jasmien Wellens, Keith R. Mehalek, Harbir S. Dhillon, Agnieszka Wozniak, Sneha S. Patil, Aya Agha, Kathleen R. Makielski, Yemarshet K. Gebreyohannes, Areej A. Ali, Anette Duensing, Jessica L. Rausch, Maria Debiec-Rychter, Yanis Tolstov, Patrick Schöffski, Donna M. Lee
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. However, most GISTs develop imatinib resistance through